Manfred Weigele

This inventor holds 18 USPTO granted patents and 14 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in TRPV3 Modulation. Top assignees: Hydra Biosciences, Inc., Ariad Pharmaceuticals, Inc., Proteotech Inc.. Active years: 1996-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Manfred Weigele. Retrieved from https://idiyas.com/inventor/manfred-weigele-541a5qjq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 14)

% Patents Active = 61.1

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 6.3

ph-index = 6

Forward Citations = 136(Granted Patents)

Company Filing History:

8 out of 49

Hydra Biosciences, Inc.

patents

5 out of 69

Ariad Pharmaceuticals, Inc.

4. 1 out of 834,570

Other

patents

Years Active: 1996-2016

Loading Chart...

Areas of Expertise:

TRPV3

Beta-Amyloid

Synucleinopathies

Pyrimido Compounds

Quinazolin Compounds

Signal Transduction

Proton Pump Inhibitors

SH2 Inhibitors

Purine Derivatives

Protein Trafficking

Modulating Compounds

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9486455 - Compounds for modulating TRPV3 function (2016-11-08),

2. 9181219 - Compounds of modulating TRPV3 function (2015-11-10),

3. 8916598 - Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies (2014-12-23),

4. 8916550 - Compounds for modulating TRPV3 function (2014-12-23),

5. 8829198 - Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies (2014-09-09),

6. 8592476 - Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies (2013-11-26),

7. 8552009 - Substituted pyrimido 4.5-d pyrimidin-4-one compounds for modulating TRPV3 function (2013-10-08),

8. 8389546 - Compounds for modulating TRPV3 function (2013-03-05),

9. 8163761 - Methods and compositions for treating disorders (2012-04-24),

10. 7998980 - Compounds for modulating TRPV3 function (2011-08-16),

11. 7893260 - Substituted quinazolin-4-one compounds for antagonizing TRPV3 function (2011-02-22),

12. 7803790 - Compounds for modulating TRPV3 function (2010-09-28),

13. 7745490 - Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies (2010-06-29),

14. 7115589 - Purine derivatives (2006-10-03),

15. 6576766 - Signal transduction inhibitors, compositions containing them (2003-06-10),

Title: The Innovative Contributions of Manfred Weigele

Introduction

Manfred Weigele is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of pharmaceutical sciences. With a total of 18 patents to his name, Weigele has made remarkable strides in developing compounds that address various medical conditions.

Latest Patents

Among his latest patents are "Compounds for Modulating TRPV3 Function" and "Compounds of Modulating TRPV3 Function." These applications focus on compounds and methods for treating pain and other conditions related to TRPV3, showcasing his commitment to advancing medical treatments.

Career Highlights

Weigele has worked with notable companies such as Hydra Biosciences, Inc. and Ariad Pharmaceuticals, Inc. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Some of his notable coworkers include Jayhong A Chong and Christopher Fanger. Their collaborative efforts have further enhanced the innovative work being done in the field.

Conclusion

Manfred Weigele's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a key innovator. His work continues to impact the treatment of pain and related conditions, making him a significant figure in the industry.

Profile summary based on public USPTO records.